These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 11331440)

  • 1. Esomeprazole (nexium).
    Med Lett Drugs Ther; 2001 Apr; 43(1103):36-7. PubMed ID: 11331440
    [No Abstract]   [Full Text] [Related]  

  • 2. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
    Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distension during gastroesophageal reflux: effects of acid inhibition and correlation with symptoms.
    Tipnis NA; Rhee PL; Mittal RK
    Am J Physiol Gastrointest Liver Physiol; 2007 Aug; 293(2):G469-74. PubMed ID: 17556589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
    Richter JE; Kahrilas PJ; Johanson J; Maton P; Breiter JR; Hwang C; Marino V; Hamelin B; Levine JG;
    Am J Gastroenterol; 2001 Mar; 96(3):656-65. PubMed ID: 11280530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study.
    Zhao J; Li J; Hamer-Maansson JE; Andersson T; Fulmer R; Illueca M; Lundborg P
    Clin Ther; 2006 Nov; 28(11):1868-76. PubMed ID: 17213007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esomeprazole magnesium (Nexium).
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(1):32-41. PubMed ID: 12120118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esomeprazole: update and clinical review.
    Baker DE
    Rev Gastroenterol Disord; 2002; 2(4):189-99. PubMed ID: 12481170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acid control with esomeprazole and lansoprazole: a comparative dose-response study.
    Wilder-Smith C; Lind T; Lundin C; Nauclér E; Nilsson-Pieschl C; Röhss K
    Scand J Gastroenterol; 2007 Feb; 42(2):157-64. PubMed ID: 17327934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Proton pump inhibitors in developmental period medicine].
    Czerwionka-Szaflarska M; Brazowski J
    Pol Merkur Lekarski; 2007 Feb; 22(128):154-8. PubMed ID: 17598663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease.
    Gilger MA; Tolia V; Vandenplas Y; Youssef NN; Traxler B; Illueca M
    J Pediatr Gastroenterol Nutr; 2008 May; 46(5):524-33. PubMed ID: 18493207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection.
    Vakil NB; Traxler BM; Levine D
    Am J Gastroenterol; 2004 Aug; 99(8):1437-41. PubMed ID: 15307856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.
    Devault KR; Johanson JF; Johnson DA; Liu S; Sostek MB
    Clin Gastroenterol Hepatol; 2006 Jul; 4(7):852-9. PubMed ID: 16682260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastroesophageal reflux disease: new treatments.
    Katz PO
    Rev Gastroenterol Disord; 2002; 2(2):66-74. PubMed ID: 12122962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. H+/K+ ATPase inhibitors in the treatment of acid-related disorders.
    Bamford M
    Prog Med Chem; 2009; 47():75-162. PubMed ID: 19328290
    [No Abstract]   [Full Text] [Related]  

  • 15. [Lansoprazol].
    Ponce J; Nos P
    Gastroenterol Hepatol; 1995 Feb; 18(2):101-9. PubMed ID: 7621274
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro-oesophageal reflux disease.
    Metz DC; Miner PB; Heuman DM; Chen Y; Sostek M
    Aliment Pharmacol Ther; 2005 Nov; 22(9):813-21. PubMed ID: 16225490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old.
    Tolia V; Gilger MA; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2010 Nov; 51(5):593-8. PubMed ID: 20706150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgery versus medical therapy for gastroesophageal reflux disease.
    DeVault KR
    Am J Gastroenterol; 2001 Jun; 96(6):1932-3. PubMed ID: 11419855
    [No Abstract]   [Full Text] [Related]  

  • 19. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study.
    Tsai HH; Chapman R; Shepherd A; McKeith D; Anderson M; Vearer D; Duggan S; Rosen JP;
    Aliment Pharmacol Ther; 2004 Sep; 20(6):657-65. PubMed ID: 15352914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA approves nexium for use in children ages 1-11 years.
    Lang L
    Gastroenterology; 2008 May; 134(5):1282. PubMed ID: 18471499
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.